Clinical and Therapeutic Impact of Large Genomic Studies at Diagnosis in Pediatric Solid Cancers — CS-PEDIA

Pediatric Solid Tumors Clinical Trial

Official title:
Evaluation of the Clinical and Therapeutic Impact of Large Genomic Studies at Diagnosis in Pediatric Solid Cancers

Status Recruiting

Clinical Trial Summary

Pediatric solid tumors with an unfavorable prognosis remain a public health issue due to their morbidity and mortality and their rapidly evolving profile. They are defined by an expected overall survival of < 30%. Progress has been made in genomic medicine with existing recommendations for the adult population, with the objective of personalized medicine. Recommendations for the pediatric population are still under consideration

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Pediatric Solid Tumors

Clinical Trial Details

NCT number	NCT06171971
Study type	Observational
Source	University Hospital, Strasbourg, France
Contact	Natacha ENTZ-WERLE, MD, PhD
Phone	33 3.88.12.87.94
Email	natacha.entz-werle@chru-strasbourg.fr
Status	Recruiting
Phase
Start date	June 20, 2022
Completion date	December 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05608148` - Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors	Phase 1
Withdrawn	`NCT02747537` - Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan	Phase 2
Completed	`NCT01049841` - Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors	Phase 1
Completed	`NCT00990912` - A Study to Document Long-Term Safety and Continued Benefit of Irinotecan and Carboplatin or Irinotecan in Subjects With Refractory Solid Tumors (Rollover Study -001, -002)	Phase 1/Phase 2
Recruiting	`NCT01050296` - Molecular Analysis Of Solid Tumors
Recruiting	`NCT04773808` - Molecular Characterization of Genetic Alterations in Pediatric Solid Tumors